Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2015
Reporting Period: Event date of October 13, 2015
This filing serves as a Regulation FD disclosure to announce a specific corporate event regarding the company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific operational milestone rather than a periodic financial statement.
Material Changes
The material change reported is the completion of enrollment in a Phase 3 clinical trial for the company's product candidate, a bio-identical oral combination of estradiol and progesterone.
Guidance, Outlook, and Management Commentary
- Operational Milestone: TherapeuticsMD, Inc. announced the completion of enrollment in its Phase 3 clinical trial for its bio-identical oral combination of estradiol and progesterone product candidate.
- Source of Information: The details are furnished via a press release dated October 13, 2015, included as Exhibit 99.1.
- Legal Status: The information is furnished pursuant to Item 7.01 and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the Phase 3 trial design and patient demographics.
- Confirm the timeline for the completion of the trial and the expected date for data readout.
- Review subsequent filings for any updates on the trial's primary endpoints or regulatory interactions.